000			nab a22 7a 4500
999			_c15989 _d15989
003			PC15989
005			20210706062658.0
008			200612b xxu||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_91233 _aHernández Hernández, Felipe _eCardiología
245	0	0	_aComparison of paclitaxel and everolimus-eluting stents in ST-segment elevation myocardial infarction and influence of thrombectomy on outcomes. ESTROFA-IM study. _h[artículo]
260			_bRevista española de cardiología (English ed.), _c2014
300			_a67(12):999-1006.
500			_aFormato Vancouver: De la Torre Hernández JM, Alfonso F, Martin Yuste V, Sánchez Recalde A, Jiménez Navarro MF, Pérez de Prado A et al; ESTROFA-IM study group. Comparison of paclitaxel and everolimus-eluting stents in ST-segment elevation myocardial infarction and influence of thrombectomy on outcomes. ESTROFA-IM study. Rev Esp Cardiol (Engl Ed). 2014 Dec;67(12):999-1006.
501			_aPMID: 25432710
504			_aContiene 31 referencias
520			_aIntroduction and objectives: We sought to compare the long-term clinical outcome of with ST-segment elevation myocardial infarction treated with paclitaxel-eluting stents or everolimus-eluting stents and the influence of thrombectomy on outcomes. Methods: The ESTROFA-IM is a multicenter retrospective registry collecting consecutive patients with infarction treated with these stents in 16 centers. Propensity-score matching was performed to select comparable stent groups and comparable groups with and without thrombectomy. Results: After matching patients, 350 treated with everolimus-eluting stents and 350 with paclitaxel-eluting stents were included in the analysis. The clinical and angiographic characteristics were comparable in both groups. The 2-year incidence of death, infarction, and target lesion revascularization was 14.9% for paclitaxel-eluting stents and 11.5% for everolimus-eluting stents (P = .04) and the incidence of definite/probable thrombosis 4.3% and 1.4%, respectively (P = .01). The use of paclitaxel-eluting was an independent predictor for events (hazard ratio = 2.44, 95% confidence interval, 1.28-4.65; P = .006). The benefit of everolimus-eluting stents over paclitaxel-eluting stents regarding stent thrombosis was more evident in the nonthrombectomy subgroup (5.4% vs 1.4%; P = .01). A significant interaction was found in the subgroups with and without thombectomy in the comparison between paclitaxel-eluting stents and everolimus-eluting stents for the end-point of stent thrombosis (P = .039). Conclusions: The results of this multicenter registry suggest better clinical outcomes with the everolimus-eluting stents in ST-segment elevation myocardial infarction. The lower risk of thrombosis with these stents could be more relevant in the absence of thrombectomy.
710			_9119 _aServicio de Cardiología
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc15989.pdf _ySolicitar documento
942			_2ddc _cART _n0